Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT
Roth-Guepin, G.; Hematology Department, CHU Brabois, Nancy, France
Canaani, J.; Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Israel
Ruggeri, A.; Acute Leukemia Working Party-EBMT and Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France
Labopin, M.; Acute Leukemia Working Party-EBMT and Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France, INSERM UMR, Paris, France, Université Pierre et Marie Curie, Paris, France
Finke, J.; Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
Cornelissen, J. J.; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology, Rotterdam, Netherlands
Delage, J.; Service d'Hématologie et d'Oncologie, Hopital Lapeyronie CHU, University Montpellier, Montpellier, France
Stuhler, G.; Deutsche Klinik für Diagnostik, KMT Zentrum, Wiesbaden, Germany
Rovira, M.; Hospital Clinic Barcelona, Institute of Hematology and Oncology, Department of Hematology, Spain
Potter, M.; Institute of Hematology and Oncology, Department of Hematology, London, United Kingdom
Stadler, M.; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Medical School, Hannover, Germany
Veelken, H.; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
Cahn, J. Y.; Department of Hematology, University Hospital, Grenoble, France
Collin, M.; Newcastle University, Adult HSCT unit, Northern Centre for Bone Marrow Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Giebel, S.; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
Nagler, A.; Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Israel, Acute Leukemia Working Party-EBMT and Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France
Mohty, M.; Acute Leukemia Working Party-EBMT and Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France, INSERM UMR, Paris, France, Université Pierre et Marie Curie, Paris, France
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: A survey from the acute leukemia working party of EBMT
Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V, Acute Leukemia Working Party, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008; 93:303-6. https://doi.org/10.3324/haematol.11960
Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009; 113:2902-5. https://doi.org/10.1182/ blood-2008-10-184093
Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, Maris MB, Laport GG, Chauncey TR, Lange T, Langston AA, Storer B, Georges GE. Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011; 96:1113-20. https://doi.org/10.3324/haematol.2011.040261
Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010; 115:206-14. https://doi.org/10.1182/blood-2009-07-232124
Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ ECOG2993 trial. Br J Haematol. 2012; 157:463-71. https:// doi.org/10.1111/j.1365-2141.2012.09095.x
Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995; 85:2025-37
Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998; 92:1556-64
Dinmohamed AG, Szabo A, van der Mark M, Visser O, Sonneveld P, Cornelissen JJ, Jongen-Lavrencic M, Rijneveld AW. Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival. Leukemia. 2016; 30:310-7. https://doi. org/10.1038/leu.2015.230
Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML, Tsai NC, Senitzer D, Snyder DS, Thomas SH, Forman SJ. Reducedintensity conditioning followed by peripheral blood stem cell transplantation for adult patients with highrisk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2009; 15:1407-14. https://doi.org/10.1016/j. bbmt.2009.07.003
Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia. 2009; 23:1763-70. https://doi.org/10.1038/leu.2009.102
Nishiwaki S, Inamoto Y, Imamura M, Tsurumi H, Hatanaka K, Kawa K, Suzuki R, Miyamura K. Reducedintensity versus conventional myeloablative conditioning for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. Blood. 2011; 117:3698-9. https://doi.org/10.1182/ blood-2011-01-329003
Marks DI, Wang T, Perez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010; 116:366-74. https://doi.org/10.1182/blood-2010-01-264077
Giebel S, Labopin M, Socie G, Beelen D, Browne P, Volin L, Kyrcz-Krzemien S, Yakoub-Agha I, Aljurf M, Wu D, Michallet M, Arnold R, Mohty M, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017; 102:139-49. https:// doi.org/10.3324/haematol.2016.145631
Paulson K, Szwajcer D, Raymond CB, Seftel MD. The role of hematopoietic cell transplantation in adult ALL: clinical equipoise persists. Leuk Res. 2014; 38:176-9. https://doi. org/10.1016/j.leukres.2013.10.021
Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106:3760-7. https://doi.org/10.1182/blood-2005-04-1623
Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014; 28:658-65. https://doi.org/10.1038/leu.2013.253
Rosko AE, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Martino Bufarull R, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017; 92:42-9. https://doi. org/10.1002/ajh.24575
Kanamori H, Mizuta S, Kako S, Kato H, Nishiwaki S, Imai K, Shigematsu A, Nakamae H, Tanaka M, Ikegame K, Yujiri T, Fukuda T, Minagawa K, et al. Reducedintensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2013; 48:1513-8. https://doi. org/10.1038/bmt.2013.140
Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007; 109:3189-97. https://doi. org/10.1182/blood-2006-10-051912
Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaresults of the prospective multicenter LALA-94 trial. Blood. 2002; 100:2357-66. https://doi.org/10.1182/blood-2002-03-0704
Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, Tabrizi R, Nagler A, Rocha V, Acute Leukemia Working Party of EBMT. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010; 116:4439-43. https://doi.org/10.1182/ blood-2010-02-266551
Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, et al. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transplant. 2013; 48:1389-94. https://doi. org/10.1038/bmt.2013.68
Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003; 102:4255-60. https://doi.org/10.1182/ blood-2002-10-3263
Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, Styczynski J, Ward KN, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014; 59:473-81. https:// doi.org/10.1093/cid/ciu364
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socie G, Schwerdtfeger R, Kroger N, Ganser A, Niederwieser D, Polge E, Blau IW, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013; 122:3359-64. https://doi. org/10.1182/blood-2013-05-499830
Bjorklund AT, Clancy T, Goodridge JP, Beziat V, Schaffer M, Hovig E, Ljunggren HG, Ljungman PT, Malmberg KJ. Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. J Immunol. 2016; 196:1400-11. https://doi.org/10.4049/jimmunol.1501434
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15:1628-33. https://doi. org/10.1016/j.bbmt.2009.07.004
Terwey TH, Hemmati PG, Martus P, Dietz E, Vuong LG, Massenkeil G, Dorken B, Arnold R. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica. 2010; 95:810-8. https://doi.org/10.3324/haematol.2009.011809
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106:2912-9. https://doi.org/10.1182/blood-2005-05-2004
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825-8
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-56. https://doi. org/10.1016/j.bbmt.2005.09.004
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ. Composite end point of graft-versus-host diseasefree, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015; 125:1333-8. https://doi. org/10.1182/blood-2014-10-609032
